Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCELLULAR AND MOLECULAR

Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy

Erik Lindström, Bengt von Mentzer, Ingrid Påhlman, Ingela Ahlstedt, Anna Uvebrant, Elin Kristensson, Rakel Martinsson, Anna Novén, Jennie de Verdier and Georges Vauquelin
Journal of Pharmacology and Experimental Therapeutics September 2007, 322 (3) 1286-1293; DOI: https://doi.org/10.1124/jpet.107.124958
Erik Lindström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt von Mentzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid Påhlman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingela Ahlstedt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Uvebrant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elin Kristensson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rakel Martinsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Novén
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennie de Verdier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georges Vauquelin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We compared the neurokinin 1 receptor (NK1R) antagonists aprepitant, CP-99994 [(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine], and ZD6021 [3-cyano-N-((2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(methyl-(S)-sulfinyl)phenyl]piperidino]butyl)-N-methyl]napthamide]] with respect to receptor interactions and duration of efficacy in vivo. In Ca2+ mobilization assays (fluorometric imaging plate reader), antagonists were applied to human U373MG cells simultaneously with or 2.5 min before substance P (SP). In reversibility studies, antagonists were present for 30 min before washing, and responses to SP were repeatedly measured afterward. The compounds were administered i.p. to gerbils, and the gerbil foot tap (GFT) response was monitored at various time points. The NK1R receptor occupancy for aprepitant was determined in striatal regions. Levels of compound in brain and plasma were measured. Antagonists were equipotent at human NK1R and acted competitively with SP. After preincubation, aprepitant and ZD6021 attenuated the maximal responses, whereas CP-99994 only shifted the SP concentration-response curve to the right. The inhibitory effect of CP-99994 was over within 30 min, whereas for ZD6021, 50% inhibition still persisted after 60 min. Aprepitant produced maximal inhibition lasting at least 60 min. CP-99994 (3 μmol/kg) inhibited GFT by 100% 15 min after administration, but the effect declined rapidly together with brain levels thereafter. The efficacy of ZD6021 (10 μmol/kg) lasted 4 h and correlated well with brain levels. Aprepitant (3 μmol/kg) inhibited GFT and occupied striatal NK1R by 100% for >48 h despite that brain levels of compound were below the limit of detection after 24 h. Slow functional reversibility is associated with long-lasting in vivo efficacy of NK1R antagonists, whereas the efficacy of compounds with rapid reversibility is reflected by their pharmacokinetics.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.124958.

  • ABBREVIATIONS: SP, substance P; NK, neurokinin; NK1R, NK1 receptor; SR 140333, nolpitantium; GFT, gerbil foot tap; CP-99994, (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine; BSA, bovine serum albumin; FLIPR, fluorometric imaging plate reader; ASMSP, acetyl-[Arg6,Sar9,Met(O2)11]-SP6–11; LC, liquid chromatography; CNS, central nervous system; MEN 11149, (2-(2-naphthyl)-1-N-{(1R,2S)-2-N-[1(H)indol-3-yl-carbonyl]aminocyclohexanecarbonyl}-1-[N′-methyl-N′-(4-methylphenylacetyl)]diaminoethane; ZD6021, 3-cyano-N-((2S)-2-(3,4-dichlorophenyl)-4-[4-[2-(methyl-(S)-sulfinyl)phenyl]piperidino]butyl)-N-methyl]napthamide]; CP122,721, (+)-(2S,3S)-3-(2-methoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine.

  • Received April 27, 2007.
  • Accepted June 14, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 385 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 385, Issue 1
1 Apr 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCELLULAR AND MOLECULAR

Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy

Erik Lindström, Bengt von Mentzer, Ingrid Påhlman, Ingela Ahlstedt, Anna Uvebrant, Elin Kristensson, Rakel Martinsson, Anna Novén, Jennie de Verdier and Georges Vauquelin
Journal of Pharmacology and Experimental Therapeutics September 1, 2007, 322 (3) 1286-1293; DOI: https://doi.org/10.1124/jpet.107.124958

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCELLULAR AND MOLECULAR

Neurokinin 1 Receptor Antagonists: Correlation between in Vitro Receptor Interaction and in Vivo Efficacy

Erik Lindström, Bengt von Mentzer, Ingrid Påhlman, Ingela Ahlstedt, Anna Uvebrant, Elin Kristensson, Rakel Martinsson, Anna Novén, Jennie de Verdier and Georges Vauquelin
Journal of Pharmacology and Experimental Therapeutics September 1, 2007, 322 (3) 1286-1293; DOI: https://doi.org/10.1124/jpet.107.124958
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Chlorogenic Acid Inhibits Breast Cancer Metastasis
  • SNAP25 and mGluRs Control Pathological Tau Release
  • N-Stearoylethanolamine Inhibits Platelet Reactivity
Show more Cellular and Molecular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics